In today’s partnering environment, strong data alone no longer secures high value pharma deals. Successful assets are differentiated by the clarity and credibility of the commercial story behind them. This session brings together experienced dealmakers to explore how leading biotech teams translate clinical promise into narratives that resonate with potential pharma partners and investors. Through recent deal examples, the panel will examine how articulating the commercial story of the asset in a credible and realistic way, and how demonstrating execution understanding can accelerate trust and momentum, and shape deal success.
Tuesday, May 5, 16:00 - 16:45, room Kairo
| Name | Position | Institution |
|---|---|---|
| Marek Rombel | Managing Director, Commercial Advisory Group | Syneos Health Consulting |
| Name | Position | Institution |
|---|---|---|
| Martijn Negen | Chief Operating Officer | VarmX |
| Artal Moreno-Fortuny | Executive Director, Business Development & Strategy | Alesta Therapeutics |
| Marc Hennebert | Managing Director, Commercial Advisory Group | Syneos Health Consulting |
| Sanifit |
Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work globally, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more, visit syneoshealth.com. Shortening the distance from lab to life®.
